Critical evaluation of latanoprostene bunod in the treatment of glaucoma.
Critical evaluation of latanoprostene bunod in the treatment of glaucoma.
复制标题
拉坦前列烯Bunod在青光眼治疗中的批判性评估。
DOI：
10.2147/opth.s103985
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Lin KY
中科院分区：
文献类型：
--
作者：
Garcia GA;Ngai P;Mosaed S;Lin KY
拉坦前列素 (LBN) 是一种新型的一氧化氮供体前列腺素 F2α 受体激动剂，处于临床开发阶段，用于降低开角型青光眼和高眼压症的眼内压。目前，LBN 在美国、欧盟和日本正在进行 III 期临床试验，在保持安全性和耐受性的同时，显示出良好的疗效。我们回顾了临床前和临床开发工作，并评估了 LBN 单一疗法在开角型青光眼和高眼压症治疗中的潜在作用。当前的 LBN 临床开发计划包括八项试验，其中四项已发表完整的方法和结果。我们还汇总了不良事件数据，以确定三项关键研究的发生率。迄今为止的证据表明，LBN 可能是一种安全有效的降眼压药，尽管其潜在的神经保护作用和对视野丧失的影响仍有待评估。
Latanoprostene bunod (LBN) is a novel nitric oxide-donating prostaglandin F2α receptor agonist in clinical development for intraocular pressure lowering in open-angle glaucoma and ocular hypertension. Currently in Phase III clinical trials in the USA, European Union, and Japan, LBN has demonstrated promising efficacy while maintaining safety and tolerability. We review preclinical and clinical developmental efforts and evaluate the potential role of LBN monotherapy in the management of open-angle glaucoma and ocular hypertension. The current LBN clinical development program comprises eight trials, four of which have resulted in publication of complete methodology and outcomes. We additionally pool adverse events data to determine incidences across three pivotal studies. Evidence thus far indicates that LBN may be a safe and effective ocular hypotensive agent, although the potential neuroprotective effects and the impact on visual field loss remain to be evaluated.